Persistent facial redness, visible blood vessels, pustules that look like acne but won't respond to acne treatment — rosacea is chronic but very controllable with the right triggers identified and the right topicals prescribed.
Rosacea presents differently in each patient. We subtype accurately and treat each presentation with its specific evidence-based therapy.
Persistent central facial redness, flushing, and visible small blood vessels without papules or pustules. Managed with brimonidine or oxymetazoline gel to reduce redness, sun protection, and trigger diary.
The "acne rosacea" subtype — inflammatory papules and pustules on a background of redness. Treated with topical metronidazole or azelaic acid; low-dose doxycycline for moderate-severe cases. Never isotretinoin as first-line.
Skin thickening and sebaceous gland hypertrophy — most commonly the nose (rhinophyma) but also chin and forehead. Medical management to prevent progression; surgical referral for established rhinophyma.
Eye involvement in rosacea — blepharitis, conjunctival injection, and meibomian gland dysfunction causing dry, gritty eyes. We co-manage with ophthalmology: lid hygiene, omega-3 supplements, low-dose doxycycline.
Skin that stings, burns, or reddens easily in response to cosmetics, temperature change, or skincare — without overt rosacea features. We rebuild barrier function and design a minimal, evidence-based daily skincare routine.
Elevated Demodex folliculorum mite density contributes to papulopustular rosacea. Topical ivermectin 1% cream (Soolantra) specifically targets Demodex while also reducing inflammation — often superior to metronidazole for this subgroup.
We classify rosacea into ETR, PPR, phymatous, or ocular subtypes using clinical examination — because treatment is fundamentally different for each. Dermoscopy helps identify telangiectasia pattern and Demodex density.
Standard rosacea triggers: UV, heat, spicy food, alcohol, exercise, stress, certain skincare ingredients. We give every patient a structured trigger diary to identify their personal pattern over 4 weeks.
Metronidazole 0.75–1% gel, azelaic acid 15–20% gel, or ivermectin 1% cream — chosen by subtype and severity. For ETR, brimonidine 0.33% gel reduces background erythema within 30 minutes of application.
Subantimicrobial dose doxycycline 40 mg modified-release (anti-inflammatory, not antibiotic dose) for moderate-severe PPR. We avoid long-term standard antibiotics to prevent resistance.
Most rosacea patients are using too many products — many aggravating their condition. We simplify to: gentle cleanser, mineral SPF 50, and the prescribed topical. No acids, retinoids, or physical exfoliants initially.
For telangiectasia and persistent diffuse erythema that doesn't respond to topicals, we coordinate referral for IPL (intense pulsed light) treatment which targets dilated vessels directly.
Many patients are told to avoid triggers and given a cleanser — we go further with accurate subtyping, evidence-based prescribing, and a structured long-term plan.
We use dermoscopy to identify telangiectasia pattern, follicular changes, and Demodex — choosing the most effective treatment from the outset rather than trial and error.
Every patient receives a 4-week trigger diary to identify their personal pattern — because triggers vary significantly between individuals and guessing wastes months of management time.
We prescribe topical ivermectin 1% (superior to metronidazole for Demodex-dense rosacea) — a newer therapy not yet widely available through general practitioners in this region.
We cut harmful routines down to 3 products maximum in the active phase — preventing the "skincare overwhelm" that is one of the most common rosacea aggravators.
| Criterion | Supreme Elite Clinic | GP Antibiotic Course | Skincare Brand Protocol | Steroid Cream (Wrong Rx) |
|---|---|---|---|---|
| Accurate subtype diagnosis | ✓ 4 subtypes classified | Partial — PPR often correct | ✗ Not clinical | ✗ Misdiagnosis |
| Trigger diary & avoidance | ✓ Structured 4-week diary | Verbal advice only | ✗ Product-focused | ✗ None |
| Topical metronidazole / ivermectin | ✓ Prescribed correctly | Sometimes | ✗ Not prescribers | ✗ Wrong drug class |
| Sub-antimicrobial doxycycline | ✓ Anti-inflammatory dose | ✗ Full antibiotic dose (resistance risk) | ✗ Not available | ✗ None |
| Risk of steroid rosacea | ✓ Never prescribe facial steroids | Low — if correctly diagnosed | ✗ Possible via OTC products | ✗ High — worsens rosacea |
| IPL / vascular referral | ✓ Coordinated when needed | ✗ Rarely arranged | ✗ Not available | ✗ None |
Applied once daily, ivermectin targets Demodex mites and reduces inflammatory lesions. Superior to metronidazole in head-to-head trials for papulopustular rosacea and maintains remission longer.
PPR / DemodexAn alpha-2 agonist that constricts dilated facial blood vessels within 30 minutes, providing up to 12 hours of redness reduction for ETR. Not a cure — used as needed for social or occupational situations.
ETR / Erythema40 mg modified-release doxycycline is used at an anti-inflammatory dose — below the threshold for antibiotic activity — reducing papules and pustules without contributing to antibiotic resistance or gut flora disruption.
Moderate–Severe PPRUV is the most universal rosacea trigger. We prescribe mineral (zinc oxide / titanium dioxide) sunscreen — which doesn't sting sensitive skin unlike chemical filters — and green-tinted formulations to neutralise redness immediately.
All SubtypesUV exposure, heat & hot drinks, spicy food, alcohol (especially red wine), exercise, stress, and certain skincare ingredients (alcohol, fragrance, menthol, SLS). Identifying your personal top 3 triggers has more impact than any medication alone.
Book a consultation today. Call +91 96774 73344 or book online.
